Merck & Co., Inc. (ETR:6MK)
Germany
· Delayed Price · Currency is EUR 67.60
+1.00 (1.50%)
May 16, 2025, 5:35 PM CET
Merck & Co. Employees
As of December 31, 2024, Merck & Co. had 75,000 total employees, including 73,000 full-time and 2,000 part-time employees. The number of employees increased by 3,000 or 4.17% compared to the previous year.
Employees
75,000
Change (1Y)
3,000
Growth (1Y)
4.17%
Revenue / Employee
€799,198
Profits / Employee
€217,972
Market Cap
171.37B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 75,000 | 3,000 | 4.17% |
| Dec 31, 2023 | 72,000 | 3,000 | 4.35% |
| Dec 31, 2022 | 69,000 | 1,000 | 1.47% |
| Dec 31, 2021 | 68,000 | -6,000 | -8.11% |
| Dec 31, 2020 | 74,000 | 3,000 | 4.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Healthineers AG | 72,000 |
| Merck KGaA | 59,020 |
| Fresenius SE & Co. KGaA | 176,486 |
| Bayer Aktiengesellschaft | 90,587 |
| Fresenius Medical Care AG | 111,513 |
| Sartorius Aktiengesellschaft | 13,528 |
| Carl Zeiss Meditec AG | 5,730 |
| Fielmann Group AG | 24,363 |
Merck & Co. News
- 2 days ago - Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - Wallstreet:Online
- 2 days ago - Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society's (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension - Business Wire
- 2 days ago - Decoding Merck & Co's Options Activity: What's the Big Picture? - Benzinga
- 3 days ago - Merck says late-stage trial for Keytruda regimen hit main goal in ovarian cancer - Seeking Alpha
- 3 days ago - Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers - Benzinga
- 3 days ago - Merck Announces Phase 3 KEYNOTE-B96 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Platinum-Resistant Recurrent Ovarian Cancer Whose Tumors Expressed PD-L1 and in All Comers - Business Wire
- 3 days ago - From Cancer Drugs To Cosmetics: A Cash-strapped Company's Makeover Story - Benzinga
- 3 days ago - FDA Approves Merck’s WELIREG (belzutifan) for the Treatment of Adults and Pediatric Patients 12 Years and Older With Locally Advanced, Unresectable, or Metastatic Pheochromocytoma or Paraganglioma (PPGL) - Wallstreet:Online